Tempest Therapeutics, Inc. announced that its stockholders have approved several key proposals at its 2026 Annual Meeting, including the potential issuance of a significant number of shares related to two separate financing agreements.
Key Details
- Lincoln Park Agreement: Shareholders approved the potential issuance and sale of 20% or more of the company's outstanding common stock pursuant to a purchase agreement with Lincoln Park Capital Fund, LLC.
- PIPE Warrant Issuance: Approval was granted for the issuance of up to 6,428,573 shares of common stock related to a private placement dated September 11, 2026. This includes shares issuable upon exercise of Series C Warrants (3,105,591), Series D Warrants (3,105,591), and placement agent warrants (217,391).
- Other Approvals: Stockholders also elected two Class II directors, John David Yee and William Drake Richey, and ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.